26
|
Boulfoul W, Baldini C, Borget I, Martin Romano P, Verlingue L, Lacroix L, Angevin E, Rouleau E, Varga A, Postel Vinay S, Gazzah A, Bahleda R, Marabelle A, Ribrag V, Vuagnat P, Champiat S, Michot JM, Hollebecque A, Soria JC, Massard C. Precision medicine for patients with primary brain tumours: Molecular screening for cancer treatment optimization (MOSCATO) prospective trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz243.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Sun R, Lancia A, Sundahl N, Milic M, Carre A, Lerousseau M, Estienne T, Battistella E, Klausner G, Bahleda R, Alvarez-Andres E, Robert C, Boutros C, Vakalopoulou M, Paragios N, Ost P, Massard C, Deutsch E. Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz239.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Bizot A, Romano-Martin P, Baldini C, Champiat S, Varga A, Gazzah A, Bahleda R, Vuagnat P, Hollebecque A, Michot JM, Ribrag V, Massard C, Vinay SP. Are epigenetic therapies modifying sensitivity to conventional chemotherapy? Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Baldini C, Younan N, Castanon Alvarez E, Bahleda R, Hollebecque A, Dhermain F, Ammari S, Alentorn A, Dumont S, Frenel J, Di Stefano A, Bielle F, Hoang-Xuan K, Delattre J, Soria J, Sanson M, Idbaih A, Massard C, Touat M. OS4.3 Feasibility and benefit of Molecular Profiling to Guide Enrollment of Patients with Recurrent Gliomas in Early Phase Trials. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
Participation of glioma patients in early phase clinical trials has recently shown to be safe, although clinical benefits reported in this population were marginal. We aimed to evaluate whether an enrichment strategy based on molecular profiling associates with improved outcome in gliomas patients participating in early phase trials.
MATERIAL AND METHODS
Records of patients enrolled in early phase trials of cytotoxic therapies, small molecule inhibitors or monoclonal antibodies from 2008 to 2017 were analyzed for clinicopathological characteristics, toxicity, response, median progression-free survival (PFS) and overall survival (OS). The primary objective was to evaluate the feasibility and benefit of using molecular profiling to guide enrollment.
RESULTS
Ninety-one patients were enrolled, of whom 47/91 (51.6%) were molecularly oriented. Molecular targets included IDH1/2 (n=15) and BRAF (11) mutations, FGFR1-3 fusions (n= 10) and mutations (n = 4), mismatch repair deficiency (8), and MDM2 amplification (1). Grade 3/4 adverse events were reported in 9/91 (9.9%) patients. In patients with IDH1/2-wild-type high-grade glioma (n=45), the overall response rate (24.0% [95% CI 11.5–43.4] vs 0.0% [95% CI 0.0–16.1], P=0.027) was significantly higher in molecularly-oriented vs non-molecularly-oriented patients. Updated outcome results, and clinical and molecular factors associated with response, PFS and OS in multivariate analyses will be presented at the conference.
CONCLUSION
Using molecular profiling to guide enrollment in early phase trials is feasible and offers potential benefit to gliomas patients. Further studies are warranted to identify the population most likely to benefit from this approach.
Collapse
|
30
|
Michot J, Camara-Clayette V, Detolle A, Chahine C, Lazarovici J, Danu A, Bosq J, Ghez D, Romano-Martin P, Dartigues P, Arfi-Rouche J, Bahleda R, Rahali W, Varga A, Baldini C, Tselikas L, Paume C, Lecourt H, Cotteret S, Vergé V, Soria J, Massard C, Ribrag V. FEASIBILITY AND BENEFIT OF MOLECULARLY-INFORMED ENROLLMENT INTO EARLY PHASE CLINICAL TRIALS FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.142_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
31
|
Tran B, Meric-Bernstam F, Arkenau HT, Bahleda R, Kelley R, Hierro C, Ahn D, Zhu A, Javle M, Winkler R, He H, Huang J, Goyal L. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Colevas A, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau N, Sarkar I, Molinero L, Grossman W, Kabbinavar F, Fassò M, O’Hear C, Powderly J. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol 2018; 29:2247-2253. [DOI: 10.1093/annonc/mdy411] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
|
33
|
Vuagnat P, Baldini C, Verlingue L, Martin Romano P, Varga A, Hollebecque A, Postel-Vinay S, Gazzah A, Bahleda R, Marabelle A, Ribrag V, Champiat S, Michot JM, Soria JC, Massard C. Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Bernard-Tessier A, Baldini C, Castanon Alvarez E, Ammari S, Martin Romano P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C. Patterns of progression to immune checkpoint targeted monoclonal antibodies in phase I trials. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Vozy A, Simonaggio A, Auclin E, Mezquita L, Baldini C, Martin-Romano P, Pistilli B, Gazzah A, Bahleda R, Ribrag V, Postel-Vinay S, Champiat S, Soria JC, André F, Massard C, Besse B, Delaloge S, Varga A. Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.286] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Meric-Bernstam F, Arkenau H, Tran B, Bahleda R, Kelley R, Hierro C, Ahn D, Zhu A, Javle M, Winkler R, He H, Huang J, Goyal L. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy149] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Gauci ML, Lanoy E, Champiat S, Michot JM, Varga A, Bahleda R, Angevin E, Gazzah A, Verlingue L, Bigot F, Aspeslagh S, Castanon E, Baldini C, Postel-Vinay S, Massard C, Hollebecque A, Soria JC, Marabelle A. Long term survival in patients responding to an Anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Herin H, Castanon E, Dyevre V, Aspeslagh S, Marabelle A, Postel-Vinay S, Varga A, Gazzah A, Ribrag V, Bahleda R, Michot JM, Mir O, Massard C, Hollebecque A, Soria JC, Baldini C. Immunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Faure M, Hollebecque A, Bahleda R, Soria JC, Dyevre V. FGFR pathway genomic aberrations and response to FGFRs inhibitors. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx390.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Bahleda R, Braiteh F, Balmanoukian A, Braña I, Hodi F, Garbo L, Liu B, Molinero L, O'Hear C, Shen X, Colevas A. Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx374.001a] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
El Dakdouki Y, Verlingue L, Massard C, Bahleda R, Hollebecque A, Mahjoubi L, Rouleau E, Lacroix L, Auger N, Scoazec JY, Solary E, Marabelle A, André F, Soria JC, Postel-Vinay S. Landscape of DNA damage response (DDR) genes alterations in the prospective MOSCATO and MATCH R trials. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx391.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Gazzah A, Boni V, Soria J, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E. Phase Ib study of afatinib plus standard-dose cetuximab in patients with advanced solid tumours. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)33014-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
43
|
Isakoff S, Bahleda R, Saleh M, Bordoni R, Shields A, Dauer J, Curley M, Baum J, McClure T, Louis C, Soria J. A phase 1 study of MM-141, a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3, in relapsed or refractory solid tumors. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)33008-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
44
|
Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, Evans TRJ, Zalcman G, Bahleda R, Hollebecque A, Lemech C, Dean E, Brown J, Gibson D, Peddareddigari V, Murray S, Nebot N, Mazumdar J, Swartz L, Auger KR, Fleming RA, Singh R, Millward M. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncol 2016; 27:2268-2274. [PMID: 27733373 DOI: 10.1093/annonc/mdw427] [Citation(s) in RCA: 97] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Revised: 08/30/2016] [Accepted: 08/31/2016] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Focal adhesion kinase (FAK) is important in cancer growth, survival, invasion, and migration. The purpose of this study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the FAK inhibitor, GSK2256098, in cancer patients. PATIENTS AND METHODS The dose of GSK2256098 was escalated, in cohorts of patients with advanced cancer, from 80 to 1500 mg, oral twice daily (BID), until the MTD was determined. Serial blood samples were obtained from all patients, and the PK was determined. Paired tumor biopsies were obtained in select patients, and the level of phospho-FAK (pFAK) was determined. RESULTS Sixty-two patients (39 males, 23 females; median age 61 y.o., range 21-84) received GSK2256098. Dose-limiting toxicities of grade 2 proteinuria (1000 mg BID), grade 2 fatigue, nausea, vomiting (1250 mg BID), and grade 3 asthenia and grade 2 fatigue (1500 mg BID) were reported with the MTD identified as 1000 mg BID. The most frequent adverse events (AEs) were nausea (76%), diarrhea (65%), vomiting (58%), and decreased appetite (47%) with the majority of AEs being grades 1-2. The PK was generally dose proportional with a geometric mean elimination half-life range of 4-9 h. At the 750, 1000, and 1500 mg BID dose levels evaluated, the pFAK, Y397 autophosphorylation site, was reduced by ∼80% from baseline. Minor responses were observed in a patient with melanoma (-26%) and three patients with mesothelioma (-13%, -15%, and -17%). In the 29 patients with recurrent mesothelioma, the median progression-free survival was 12 weeks with 95% CI 9.1, 23.4 weeks (23.4 weeks merlin negative, n = 14; 11.4 weeks merlin positive, n = 9; 10.9 weeks merlin status unknown, n = 6). CONCLUSIONS GSK2256098 has an acceptable safety profile, has evidence of target engagement at doses at or below the MTD, and has clinical activity in patients with mesothelioma, particularly those with merlin loss.
Collapse
|
45
|
Bigot F, Alvarez EC, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S, Varga A, Bahleda R, Gazzah A, Bonnet C, Michot JM, Marabelle A, Soria JC, Massard C. Identification of new prognostic factors in phase I patients treated by immunotherapy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.33] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Bonnet C, Alvarez EC, Michot JM, Bigot F, Varga A, Gazzah A, Bahleda R, Marabelle A, Hollebecque A, Aspeslagh S, Angevin E, Armand JP, Albiges L, Loriot Y, Postel-Vinay S, Soria JC, Massard C. Patients with metastatic prostate cancer enrolled in phase 1 trials: Outcomes and molecular alterations. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, Gazzah A, Bahleda R, Ileana E, Massard C, Vielh P, Soria J, Besse B. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer 2015; 89:306-10. [DOI: 10.1016/j.lungcan.2015.06.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2015] [Revised: 06/08/2015] [Accepted: 06/14/2015] [Indexed: 12/12/2022]
|
48
|
Deutsch E, Le Péchoux C, Faivre L, Rivera S, Tao Y, Pignon JP, Angokai M, Bahleda R, Deandreis D, Angevin E, Hennequin C, Besse B, Levy A, Soria JC. Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. Ann Oncol 2015; 26:1223-1229. [PMID: 25701455 DOI: 10.1093/annonc/mdv105] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2014] [Accepted: 02/12/2015] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND This phase I study evaluated the safety and efficacy of the oral mTOR inhibitor everolimus in combination with thoracic radiotherapy followed by consolidation chemotherapy in locally advanced or oligometastatic untreated non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Everolimus dose was escalated in incremental steps [sequential cohorts of three patients until the occurrence of dose-limiting toxicity (DLT)] and administered orally weekly (weekly group: dose of 10, 20 or 50 mg) or daily (daily group: 2.5, 5 or 10 mg), 1 week before, and during radiotherapy until 3.5 weeks after the end of radiotherapy. Two cycles of chemotherapy (cisplatin-navelbine) were administrated 4.5 weeks after the end of radiotherapy. RESULTS Twenty-six patients were included in two centers, 56% had adenocarcinoma and 84% had stage III disease. In the weekly group (12 assessable patients), everolimus could be administered safely up to the maximum planned weekly dose of 50 mg; however, one patient experienced a DLT of interstitial pneumonitis at the weekly dose level of 20 mg. In the daily group (9 assessable patients): one DLT of interstitial pneumonitis with a fatal outcome was observed at the daily dose level of 2.5 mg; two other DLTs (one grade 3 esophagitis and one bilateral interstitial pneumonitis) were found at the daily dose level of 5 mg. Overall there were five patients with G3-4 interstitial pneumonitis related to treatment. Among 22 assessable patients for response, there were 9 (41%) partial response and 7 (32%) stable disease. At a median follow-up of 29 months, the 2-year overall survival and progression-free survival actuarial rates were 31% and 12%, respectively. CONCLUSION In previously untreated and unselected NSCLC patients, the recommended phase II dose of everolimus in combination with thoracic radiotherapy is 50 mg/week. Pulmonary toxicity is of concern and should be carefully monitored to establish the potential role of mTOR inhibitor with concomitant radiotherapy. EUDRACT N 2007-001698-27.
Collapse
|
49
|
Michot JM, Benajiba L, Baldini C, Faivre L, Danu A, Hollebecque A, Massard C, Varga A, Bahleda R, Gazzah A, Soria JC, Ribrag V. Outcome of patients with relapsed/refractory lymphoma in a large cohort inside a phase 1 clinic department. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv090.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Soria JC, DeBraud F, Bahleda R, Adamo B, Andre F, Dienstmann R, Delmonte A, Cereda R, Isaacson J, Litten J, Allen A, Dubois F, Saba C, Robert R, D'Incalci M, Zucchetti M, Camboni MG, Tabernero J. Corrections to "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors". Ann Oncol 2015; 26:445. [PMID: 32590894 DOI: 10.1093/annonc/mdu547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|